Tandem Diabetes Care, Inc. (NASDAQ:TNDM) Director Rebecca B. Robertson Sells 1,500 Shares

Tandem Diabetes Care, Inc. (NASDAQ:TNDMGet Rating) Director Rebecca B. Robertson sold 1,500 shares of the company’s stock in a transaction that occurred on Monday, May 2nd. The shares were sold at an average price of $96.73, for a total value of $145,095.00. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this hyperlink.

NASDAQ:TNDM opened at $94.43 on Thursday. The company has a debt-to-equity ratio of 0.65, a current ratio of 6.15 and a quick ratio of 5.63. The firm has a market capitalization of $6.04 billion, a price-to-earnings ratio of 410.57 and a beta of 0.66. Tandem Diabetes Care, Inc. has a one year low of $76.19 and a one year high of $155.86. The business has a fifty day moving average price of $110.91 and a 200-day moving average price of $123.44.

Tandem Diabetes Care (NASDAQ:TNDMGet Rating) last posted its quarterly earnings data on Wednesday, May 4th. The medical device company reported ($0.23) EPS for the quarter, missing the consensus estimate of ($0.07) by ($0.16). The company had revenue of $175.91 million during the quarter, compared to analysts’ expectations of $168.21 million. Tandem Diabetes Care had a return on equity of 4.58% and a net margin of 2.21%. The company’s revenue for the quarter was up 24.7% on a year-over-year basis. During the same quarter last year, the company earned ($0.07) earnings per share. On average, equities research analysts expect that Tandem Diabetes Care, Inc. will post 0.56 earnings per share for the current fiscal year.

Several equities analysts recently issued reports on the company. Bank of America assumed coverage on Tandem Diabetes Care in a research report on Wednesday, March 2nd. They issued a “neutral” rating and a $130.00 price objective on the stock. Zacks Investment Research cut Tandem Diabetes Care from a “hold” rating to a “sell” rating and set a $111.00 price objective on the stock. in a research report on Tuesday, April 26th. StockNews.com assumed coverage on Tandem Diabetes Care in a research report on Thursday, March 31st. They issued a “hold” rating on the stock. Wells Fargo & Company upped their price objective on Tandem Diabetes Care from $160.00 to $166.00 and gave the company an “overweight” rating in a research report on Wednesday, February 23rd. Finally, SVB Leerink reaffirmed a “market perform” rating on shares of Tandem Diabetes Care in a research report on Monday, April 18th. Two analysts have rated the stock with a sell rating, three have issued a hold rating and seven have given a buy rating to the company’s stock. According to data from MarketBeat.com, the company presently has a consensus rating of “Hold” and a consensus target price of $141.18.

Several large investors have recently bought and sold shares of the company. BlackRock Inc. increased its stake in shares of Tandem Diabetes Care by 11.6% in the 4th quarter. BlackRock Inc. now owns 6,478,638 shares of the medical device company’s stock worth $975,164,000 after purchasing an additional 672,004 shares in the last quarter. Capital World Investors increased its stake in shares of Tandem Diabetes Care by 4.0% in the 4th quarter. Capital World Investors now owns 3,427,129 shares of the medical device company’s stock worth $515,851,000 after purchasing an additional 133,133 shares in the last quarter. Invesco Ltd. increased its stake in shares of Tandem Diabetes Care by 11.8% in the 4th quarter. Invesco Ltd. now owns 1,942,971 shares of the medical device company’s stock worth $292,456,000 after purchasing an additional 205,453 shares in the last quarter. State Street Corp increased its stake in shares of Tandem Diabetes Care by 2.2% in the 4th quarter. State Street Corp now owns 1,648,252 shares of the medical device company’s stock worth $248,095,000 after purchasing an additional 35,825 shares in the last quarter. Finally, RTW Investments LP boosted its holdings in Tandem Diabetes Care by 1.2% in the 3rd quarter. RTW Investments LP now owns 1,160,734 shares of the medical device company’s stock worth $138,568,000 after buying an additional 13,326 shares during the period. Hedge funds and other institutional investors own 94.62% of the company’s stock.

About Tandem Diabetes Care (Get Rating)

Tandem Diabetes Care, Inc, a medical device company, designs, develops, and commercializes various products for people with insulin-dependent diabetes in the United States and internationally. The company's flagship product is the t:slim X2 insulin delivery system, a pump platform that comprises t:slim X2 pump, its 300-unit disposable insulin cartridge, and an infusion set.

Recommended Stories

Insider Buying and Selling by Quarter for Tandem Diabetes Care (NASDAQ:TNDM)

Receive News & Ratings for Tandem Diabetes Care Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Tandem Diabetes Care and related companies with MarketBeat.com's FREE daily email newsletter.